View Archive »
About The Cover
The cover for issue 4 of Oncotarget features Figure 6, "Bliss Independence analysis to evaluate synergistic activity between ABT-263 (navitoclax) and A-1210477," by Ow, et al.
|
|
Table of Contents
Editorial
|
| Individualized prognostic calculators in the precision oncology era |
|
https://doi.org/10.18632/oncotarget.26581
|
| 415-416 |
Research Perspectives
|
| The effects of genomic germline variant reclassification on clinical cancer care |
|
https://doi.org/10.18632/oncotarget.26501
|
| 417-423 |
Research Papers
|
| Inhibition of 5lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of cJun Nterminal kinase |
|
https://doi.org/10.18632/oncotarget.13422
|
| 424-436 |
|
| A singlecenter experience of posttransplant lymphomas involving the central nervous system with a review of current literature |
|
https://doi.org/10.18632/oncotarget.26522
|
| 437-448 |
|
| Imbalanced sphingolipid signaling is maintained as a core proponent of a cancerous phenotype in spite of metabolic pressure and epigenetic drift |
|
https://doi.org/10.18632/oncotarget.26533
|
| 449-479 |
|
| Fibroblast growth factor receptor 1 FGFR1 as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland |
|
https://doi.org/10.18632/oncotarget.26558
|
| 480-493 |
|
| Optimal targeting of BCLfamily proteins in head and neck squamous cell carcinoma requires inhibition of both BCLxL and MCL1 |
|
https://doi.org/10.18632/oncotarget.26563
|
| 494-510 |
|
| Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer |
|
https://doi.org/10.18632/oncotarget.26566
|
| 511-526 |
|
| Polymorphism of DNA repair genes in breast cancer |
|
https://doi.org/10.18632/oncotarget.26568
|
| 527-535 |
|
| A structural model of the immune checkpoint CD160–HVEM complex derived from HDXmass spectrometry and molecular modeling |
|
https://doi.org/10.18632/oncotarget.26570
|
| 536-550 |
Case Reports
|
| Sustained response of three pediatric BRAFV600E mutated highgrade gliomas to combined BRAF and MEK inhibitor therapy |
|
https://doi.org/10.18632/oncotarget.26560
|
| 551-557 |
Corrections
|
| Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis |
|
https://doi.org/10.18632/oncotarget.26597
|
| 558-558 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
